

Pulmonx Closes \$20M Senior Secured Term Loan Agreement with Oxford Finance

SWITZERLAND USA

Published on September 19, 2014



Pulmonx, a Redwood City, California, and Neuchatel, Switzerland-based developer of minimally invasive medical devices

and technologies for the diagnosis and treatment of pulmonary disorders, closed a \$20m senior secured term loan agreement with **Oxford Finance LLC**.

The company intends to use the funds to support the U.S. clinical trial of its Zephyr Endobronchial Valve used for the treatment of emphysema and to expand its business worldwide.

Led by Oern Stuge, M.D., Interim CEO, Pulmonx focuses on developing and marketing the Chartis System and Zephyr® EBV, a diagnostic and therapeutic solution to solve the problem of emphysema-induced hyperinflation.

The therapy involves bronchoscopic placement of one-way valves to reduce the hyperinflation in the diseased portion of the lungs, thereby improving the ability of the healthier portions of the lungs to function.

The solution received the CE Mark in 2003 and is in an investigational phase in the United States.

FinSMEs